Arcutis Biotherapeutics, Inc.
ARQT Healthcare Biotechnology
Arcutis Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 91.3% from fiscal 2024. In the quarter to June 2026, revenue grew 59.3%, EPS grew 184.6%, free cash flow grew 228.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for three consecutive years, operating cash flow growth for three.
Follow ARQT
Arcutis Biotherapeutics, Inc. (ARQT) P/E ratio
As of 16 October 2026, Arcutis Biotherapeutics, Inc. (ARQT) trades at a P/E ratio of 131×. Over the past ten years it has ranged from 0.0× (June 2026) to 132× (October 2026); the current reading is higher than 100% of that period. That is above the Biotechnology industry median of 8.5× and above the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 119× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 12 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VKTX Viking Therapeutics, Inc. compare | n/m |
| LEGN Legend Biotech Corporation Sponsored ADR compare | n/m |
| TNGX Tango Therapeutics, Inc. compare | n/m |
| TARS Tarsus Pharmaceuticals, Inc. compare | n/m |
| RLAY Relay Therapeutics, Inc. compare | n/m |
| XENE Xenon Pharmaceuticals Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. compare | 8.5× |
| ARQT Arcutis Biotherapeutics, Inc. | 131× |
| TLX Telix Pharmaceuticals Limited compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)